Point72 Asset Management L.P. reduced its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 18.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,645,275 shares of the biotechnology company’s stock after selling 380,131 shares during the period. Point72 Asset Management L.P. owned 2.55% of Sarepta Therapeutics worth $74,630,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of SRPT. Jennison Associates LLC boosted its position in shares of Sarepta Therapeutics by 103.9% in the 3rd quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after purchasing an additional 582,894 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Sarepta Therapeutics during the third quarter worth about $26,011,000. Voya Investment Management LLC lifted its holdings in Sarepta Therapeutics by 2,786.1% during the second quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after acquiring an additional 548,826 shares in the last quarter. Gilder Gagnon Howe & Co. LLC lifted its holdings in Sarepta Therapeutics by 3,599.4% during the third quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock worth $24,226,000 after acquiring an additional 519,650 shares in the last quarter. Finally, HealthCor Management L.P. lifted its holdings in Sarepta Therapeutics by 31.1% during the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after acquiring an additional 481,890 shares in the last quarter. Institutional investors and hedge funds own 82.02% of the company’s stock.
Shares of Sarepta Therapeutics Inc (SRPT) opened at $54.26 on Monday. Sarepta Therapeutics Inc has a twelve month low of $26.26 and a twelve month high of $57.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44.
Several research analysts have weighed in on the company. HC Wainwright assumed coverage on Sarepta Therapeutics in a report on Friday, December 1st. They set a “buy” rating and a $75.00 target price on the stock. Robert W. Baird reiterated a “buy” rating and set a $101.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. Oppenheimer reiterated a “buy” rating and set a $76.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 16th. Goldman Sachs Group reiterated a “buy” rating and set a $71.00 target price on shares of Sarepta Therapeutics in a report on Friday, October 6th. Finally, ValuEngine lowered Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $64.14.
In other news, CEO Douglas S. Ingram purchased 38,138 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were bought at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the acquisition, the chief executive officer now directly owns 420,196 shares in the company, valued at approximately $22,035,078.24. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares in the company, valued at $745,181.37. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,167 shares of company stock worth $1,497,619. Corporate insiders own 9.60% of the company’s stock.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.